SaveMPDigheARNatrajanM, et al.Association of viable Mycobacterium leprae with Type 1 reaction in leprosy. Lepr Rev2016; 87: 78–92.
2.
LinderKZiaMKernWV, et al.Relapses vs. reactions in multibacillary leprosy: proposal of new relapse criteria. Trop Med Int Health2008; 13: 295–309.
3.
World Health Organization. WHO model prescribing information: drugs used in leprosy, Geneva: WHO, 1998.
4.
ShettyVPWakadeAAntiaNH. A high incidence of viable Mycobacterium leprae in post-MDT recurrent lesions in tuberculoid leprosy patients. Lepr Rev2001; 72: 337–344.
5.
LiniNShankernarayanNPDharmalingamK. Quantitative real-time PCR analysis of Mycobacterium leprae DNA and mRNA in human biopsy material from leprosy and reactional cases. J Med Microbiol2009; 58: 753–759.
6.
World Health Organization. WHO Expert Committee on leprosy: eighth report, Geneva: WHO, 2012.
7.
VijayakumaranPManimozhiNJesudasanK. Incidence of late lepra reaction among multibacillary leprosy patients after MDT. Int J Lepr Other Mycobact Dis1995; 63: 18–22.
8.
WatersMF. Distinguishing between relapse and late reversal reaction in multidrug (MDT)-treated BT leprosy. Lepr Rev2001; 72: 250–253.
JoplingWHMc DougallAC. Handbook of Leprosy, 5th edn. Delhi: CBS Publishers and Distributors, 1996; 82.
11.
GrossetJH. Progress in the chemotherapy of leprosy. Int J Lepr Other Mycobact Dis1994; 62: 268–277.
12.
GrossetJHGuelpa-LaurasC-CBobinP, et al.Study of 39 documented relapses of multibacillary leprosy after treatment with rifampicin. Int J Lepr1989; 57: 607–614.
13.
ReddyPKCherianA. Relapse in leprosy after multidrug therapy and its differential diagnosis with reversal reaction. Indian J Lepr1991; 63: 61–69.
14.
ShettyVPKhambatiFAGhateSD, et al.The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; Part 3–study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT+ steroids vs MDT alone, assessed at 6 months post–release from 12 months MDT. Lepr Rev2010; 80: 41–59.
15.
JiBLevyLGrossetJH. Chemotherapy of leprosy: progress since the Orlando Congress, and prospects for the future. Int J Lepr Other Mycobact Dis1996; 64: S80–88.
